Evidence map›Paper›PMID 36558967›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients.

Sahar H Elhini, Engy A Wahsh, Ahmed A Elberry, Nadia F El Ameen, Ahmed Abdelfadil Saedii, Shereen Mahmoud Refaie, Asmaa A Elsayed, Hoda M Rabea

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 7 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 7 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies.Diabetes spectrum : a publication of the American Diabetes Association · 2024
    Article
  19. Influence of the Bile Acid Transporter GenesJournal of personalized medicine · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Sahar H ElhiniDiabetes and Endocrinology Unit, Internal Medicine Department, Faculty of Medicine, Minia University, Minia 61111, Egypt.
Engy A WahshClinical Pharmacy Department, Faculty of Pharmacy, October 6 University, Giza 12525, Egypt.
Ahmed A ElberryClinical Pharmacology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62551, Egypt.ORCID 0000-0002-0073-3066
Nadia F El AmeenRadiology Department, Faculty of Medicine, Minia University, Minia 61111, Egypt.
Ahmed Abdelfadil SaediiClinical Pathology Department, Faculty of Medicine, Minia University, Minia 61111, Egypt.
Shereen Mahmoud RefaieDepartment of Biomedical Sciences, College of Medicine, King Faisal University, Hofuf 31982, Saudi Arabia.
Asmaa A ElsayedClinical Pharmacy Department, Faculty of Pharmacy, Sohag University, Sohag 82511, Egypt.
Hoda M RabeaClinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62551, Egypt.ORCID 0000-0003-0432-8970
Minia University · EGBeni-Suef University · EGKing Faisal University · SAOctober 6 University · EGSohag University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is related to metabolic syndrome via insulin resistance, where preventing disease progression is crucial in the management process. The study included 240 NAFLD patients with type 2 diabetes who were randomly allocated into empagliflozin 25 mg (EMPA group), ursodeoxycholic acid 250 mg (UDCA group), or the control group (placebo). The study outcomes included: changes in liver fat content (LFC; %) (utilizing the Dixon-based MRI-PDFF approach), liver enzymes, lipid and glycemic profiles, FIB-4 index, and non-alcoholic fatty liver score (NFS). All endpoints were assessed at baseline and after 6 months. EMPA outperformed UDCA and placebo in decreasing LFC (−8.73% vs. −5.71% vs. −1.99%; p < 0.0001). In post-treatment ultrasound images and MRI-PDFF calculations, more patients had normal fatty liver grade (no steatosis or LFC < 6.5%) with EMPA compared to UDCA. EMPA and UDCA showed significant regression in the FIB-4 index (−0.34 vs. −0.55; p = 0.011) and NFS scores (−1.00 vs. −1.11; p = 0.392), respectively. UDCA achieved higher reductions in insulin resistance than EMPA (p = 0.03); however, only EMPA significantly increased beta-cell function (54.20; p = 0.03). When exploring the differences between the two drugs, EMPA was better in decreasing LFC (%), while UDCA achieved higher reductions in liver fibrosis scores. Both showed a similar safety profile in managing liver steatosis.

Indexed as

empagliflozinMRI-PDFFNAFLDtype 2 diabetesursodeoxycholic acid

Identifiers

PMID36558967
PMCPMC9786599
OpenAlexW4311630723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.